Intravenous BCG Vaccination of Diversity Outbred Mice Results in Moderately Enhanced Protection against Challenge with Mycobacterium tuberculosis Compared to Intradermal Vaccination-Reference-Cited by-同舟云学术

Intravenous BCG Vaccination of Diversity Outbred Mice Results in Moderately Enhanced Protection against Challenge with Mycobacterium tuberculosis Compared to Intradermal Vaccination

Published:2023-07-18 Issue:7 Volume:91 Page:
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Kurtz Sherry L.¹^ORCID,Mittereder Lara R.¹,Lehman Chelsea C.¹,Khan Hamda¹,Gould Victoria A.¹,Elkins Karen L.¹

Affiliation:

1. Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA

Abstract

Tuberculosis is still the leading cause of death globally from any infectious disease, despite the widespread use of the live attenuated vaccine Bacille Calmette Guerin (BCG). While BCG has some efficacy against disseminated TB disease in children, protection wanes into adulthood resulting in over 1.8 million TB deaths per year.

Funder

HHS | U.S. Food and Drug Administration

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/iai.00168-23

Reference34 articles.

1. World Health Organization. 2022. Global tuberculosis report 2022.

2. A century of BCG: Impact on tuberculosis control and beyond

3. Key recent advances in TB vaccine development and understanding of protective immune responses against Mycobacterium tuberculosis